Listen to the Medical Experts
Why Is Precision Medicine
Complicated in Advanced
Prostate Cancer?
Joe O'Sullivan, MD, FRCPI, FFRRCSI, FRCR
Examine the Basis ofDisease Complexity
How Can Phenotypic Biomarkers Increase Precision Medicine in Advanced Prostate Cancer?
Ken Herrmann, MD, MBA
Explore the Utility ofPhenotypic Biomarkers
How Does PSMA Provide a Tailored Approach in Advanced Prostate Cancer?
Enrique Grande, MD, PhD
Discover the Potential of PSMAPrecision medicine is an approach that utilises diagnostic tools to select therapies for appropriate patients with the goal of optimising outcomes and minimising adverse events.1-3
Precision medicine may improve outcomes in oncology patients4-5; however, precision medicine is less prevalent in advanced prostate cancer compared to other tumor types.6-11
As treatment options for patients with advanced prostate cancer evolve,12 precision medicine may offer a more tailored approach by facilitating patient selection and helping to guide treatment decision making.13-16
References
1. Yates LR et al. Ann Oncol. 2018;29(1):30-35.
2. Jameson J et al. The practice of medicine. In: Harrison’s Principles of Internal Medicine. 20th ed. New York, NY: McGraw-Hill Education;2018:1-20.
3. Kratochwil C et al. J Nucl Med. 2016;57(8):1170-1176.
4. Stockley TL et al. Genome Med. 2016;8:109.
5. Morash M et al. J Pers Med. 2018;8(3):30.
6. Tian S et al. Cancer Cell Int. 2020;20:409.
7. Mullane SA, Van Allen EM. Curr Opin Urol. 2016;26(3):231-239.
8. Friedlander TW et al. Am Soc Clin Oncol Educ Book. 2017;37:358-369.
9. Skoulidis F, Heymach JV. Nat Rev Cancer. 2019;19(9):495-450.
10. Mambetsariev I et al. PLoS One. 2020;15(2):e0228188.
11. Yu K et al. Sci Rep. 2017;7(1):43294.
12. Teo MY et al. Annu Rev Med. 2019;70:479-499.
13. Lorente D et al. Eur Urol Focus. 2016;2(5):488-498.
14. Emmett L et al. J Nucl Med. 2019;61(6):866-872.
15. Hofman M et al. Lancet Oncol. 2018;19(6):825-833.
16. Thang SP et al. Eur Urol Oncol. 2019;2(6):670–676.
